The FDA has released the De Novo Classification Proposed Rule to clarify and streamline its de novo pathway by outlining processes and criteria for reviewing novel low- to moderate-risk devices. The rule, which is open to public comment, is expected to encourage greater use of the pathway.
FDA issues proposed rule on de novo classification
Sign up for AABB SmartBrief
News about transfusion and cellular therapies
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.